IDEXX director exercises options, sells 1,464 shares

IDEXX Laboratories director Sophie V. Vandebroek exercised a non-qualified stock option for 945 shares of common stock on February 17, 2026 at an exercise price of $333.90 per share, converting the derivative into common stock held directly.

Filing Impact

(High)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

IDEXX Laboratories director Sophie V. Vandebroek exercised a non-qualified stock option for 945 shares of common stock on February 17, 2026 at an exercise price of $333.90 per share, converting the derivative into common stock held directly.

On the same date, she executed open-market sales of 945 and 519 common shares at weighted average prices of $628.646 and $628.56 per share, respectively. After these transactions, she held 648 IDEXX common shares directly and 8,173 shares indirectly through the Sophie V. Vandebroek Revocable Trust.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 5 txns

Insider Vandebroek Sophie V.

Role Director

Sold 1,464 shs ($920K)

Approx. gross sale proceeds $920K

Approx. exercise cost $316K

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (right-to-buy)	945	$0.00	$0.00
Exercise	Common Stock	945	$333.90	$316K
Sale	Common Stock	945	$628.646	$594K
Sale	Common Stock	519	$628.56	$326K
holding	Common Stock	--	--	--

Holdings After Transaction: Non-Qualified Stock Option (right-to-buy) — 0 contracts (Direct); Common Stock — 648 shares (Direct); Common Stock — 8,173 shares (Indirect, By Sophie V. Vandebroek Revocable Trust)

Footnotes (2)

F1. Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vested in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of stockholders, whichever event was earlier.
F2. Not applicable

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did IDEXX (IDXX) director Sophie V. Vandebroek report?

Sophie V. Vandebroek reported exercising options for 945 IDEXX shares, then selling 945 and 519 common shares in open-market trades on February 17, 2026. These moves combined an option exercise with subsequent share sales on the same day.

How many IDEXX (IDXX) shares did Sophie V. Vandebroek sell in this Form 4?

She sold a total of 1,464 IDEXX common shares, in two transactions of 945 and 519 shares. Both were open-market or private sales reported with transaction code S on February 17, 2026, following an option exercise.

At what prices were the IDEXX (IDXX) shares sold by Sophie V. Vandebroek?

The reported IDEXX share sales occurred at weighted average prices of $628.646 and $628.56 per share. These prices applied to separate blocks of 945 and 519 shares sold on February 17, 2026, after the option exercise.

What option exercise did Sophie V. Vandebroek report for IDEXX (IDXX)?

She exercised a non-qualified stock option covering 945 IDEXX common shares at an exercise price of $333.90 per share. The transaction was coded M, indicating an exercise or conversion of a derivative security into common stock held directly.

How many IDEXX (IDXX) shares does Sophie V. Vandebroek own after these transactions?

After the reported trades, she directly owned 648 IDEXX common shares. In addition, she had indirect ownership of 8,173 shares held by the Sophie V. Vandebroek Revocable Trust, as disclosed in the Form 4 holding information.

What is the indirect IDEXX (IDXX) shareholding reported for Sophie V. Vandebroek?

The filing shows an indirect holding of 8,173 IDEXX common shares attributed to the Sophie V. Vandebroek Revocable Trust. This position is reported with indirect ownership type, indicating the trust, rather than direct personal registration, holds those shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/19/2026 - 06:00 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vandebroek Sophie V.

(Last)

(First)

(Middle)

ONE IDEXX DRIVE

(Street)

WESTBROOK

04092

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/17/2026		M		945	A	$333.9	2,112	D
Common Stock	02/17/2026		S		945	D	$628.646	1,167	D
Common Stock	02/17/2026		S		519	D	$628.56	648	D
Common Stock								8,173	I	By Sophie V. Vandebroek Revocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualified Stock Option (right-to-buy)	$333.9	02/17/2026		M			945	⁽¹⁾	05/10/2032	Common Stock	945	⁽²⁾	0	D

Explanation of Responses:

1. Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vested in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of stockholders, whichever event was earlier.

2. Not applicable

Remarks:

	/s/ Lily J. Lu, Attorney-in-Fact for Sophie V. Vandebroek	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR